Author | Cancer Network Staff

October 14, 2020

October 09, 2020

The use of PARP inhibitors in frontline maintenance therapy has greatly reduced the risk of recurrence in patients with ovarian cancer.

September 15, 2020

Insight on the importance of germline testing and HRD status in ovarian cancer as well as who should be tested.

September 14, 2020

Thomas Herzog, MD, reviews the statistics of ovarian cancer in the United States in 2020 including survival rates and types of tumors.